NCT03262935
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Untreated or symptomatic brain metastases; Treatment for brain metastases within 8 weeks prior to randomization- see trial for details
https://ClinicalTrials.gov/show/NCT03262935